Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This study will compare the efficacy and the safety of ABT-894 (1mg, 2mg or 4mg capsules)
administered BID to placebo in the treatment of DNP. Another treatment arm will be Duloxetine
60mg administered once daily (QD). Approximately 275 subjects will be enrolled into the study
at approximately 50 sites in both the United States and Europe. The study will be divided
into the following periods: Screening/Washout (21 days) followed by a Baseline Visit, an
8-week Treatment Period and a 1-week Follow-up Visit.